Venus Concept (Venus Concept) Risk Assessment

View and export this data going back to 2017. Start your Free Trial

What is Venus Concept Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Venus Concept is: High Risk: High uncertainty.

Competitive Comparison of Venus Concept's Risk Assessment

For the Medical Devices subindustry, Venus Concept's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Venus Concept's Risk Assessment Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Venus Concept's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Venus Concept's Risk Assessment falls into.

Venus Concept (NAS:VERO) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Venus Concept Risk Assessment Related Terms

Thank you for viewing the detailed overview of Venus Concept's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Venus Concept (Venus Concept) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Venus Concept Inc (NAS:VERO) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

N/A

Address

235 Yorkland Boulevard, Suite 900, Toronto, ON, CAN, M2J 4Y8

Website

https://www.venusconcept.com

Venus Concept Inc is a medical technology company. It develops, commercializes, and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies and related services. The company's products include NeoGraft, Venus Viva, Venus Legacy, Venus Versa, Venus Velocity, Venus Heal, Venus Bliss, ARTAS systems, and others. The company provides medical devices and treatments for hair, body, and skin-related problems. It generates a majority of its revenue from the United States.

Executives

Anthony Natale	director	235 YORKLAND BLVD., SUITE 900, TORONTO A6 M2J 4Y8
Ross Portaro	officer: President Global Sales	235 YORKLAND BLVD, SUITE 900, TORONTO Z4 M2J 4Y8
Michael Willingham Masters	10 percent owner	3060 PEACHTREE ROAD NW, SUITE 1425, ATLANTA GA 30305
Silva Rajiv De	director, officer: Chief Executive Officer	1400 ATWATER DRIVE, MALVERN PA 19355
Stanley Tyler Hollmig	director	235 YORKLAND BLVD, SUITE 900, TORONTO Z4 M2J 4Y8
Hemanth Jacob Varghese	officer: President/Chief Bus. Officer	330 JOICEY BOULEVARD, TORONTO A6 M5M2W1
Marlin Fund, Limited Partnership	10 percent owner	MASTERS CAPITAL MANAGEMENT, LLC, 3060 PEACHTREE ROAD NW, SUITE 1425, ATLANTA GA 30305
Masters Capital Management Llc	10 percent owner	3060 PEACHTREE ROAD NW, SUITE 1425, ATLANTA GA 30305
Marlin Fund Iii, Limited Partnership	10 percent owner	MASTERS CAPITAL MANAGEMENT, LLC, 3060 PEACHTREE ROAD NW, SUITE 1425, ATLANTA GA 30305
Marlin Master Fund Offshore Ii, Lp	10 percent owner	WAYSTONE CORP SV (CAYMAN) LTD, STE 5B201, FL 2, 1 NEXUS WAY, CAMANA BAY, BOX 1344, GRAND CAYMAN E9 KY1-1108
Mss Vc Spv Lp	10 percent owner	C/O MASTERS SPECIAL SITUATIONS, LLC, 3060 PEACHTREE ROAD, NW, STE.1425, ATLANTA GA 30305
Marlin Fund Ii, Limited Partnership	10 percent owner	MASTERS CAPITAL MANAGEMENT, LLC, 3060 PEACHTREE ROAD NW, SUITE 1425, ATLANTA GA 30305
Masters Special Situations, Llc	10 percent owner	3060 PEACHTREE ROAD NW, SUITE 1425, ATLANTA GA 30305
Penna Domenic Della	officer: Chief Financial Officer	235 YORKLAND BLVD., SUITE 900, TORONTO A6 M2J 4Y8
Anna Georgiadis	officer: VP, Global HR	235 YORKLAND BLVD., SUITE 900, TORONTO A6 M2J 4Y8